
    
      This phase Ia/Ib, open-label, multicenter study has two stages. The Ia stage is a
      dose-escalation study that will focus on safety, tolerability, efficacy and RP2D . Patients
      with HER2-expressing advanced solid tumor who failed from previous standard of care will be
      enrolled in the phase Ia study. DLT observation period is 28 days.
    
  